Novartis Patient Support[®]

Guide to completing the Start Form

Novartis Patient Support provides comprehensive resources designed to help your patients start, stay, and save on KISQALI.

Not an actual patient.

For questions or support, reach out to your dedicated Associate Director of Access and Reimbursement (ADAR) or contact Novartis Patient Support.

- **Phone:** 866-433-8000
- **Fax:** 800-414-3518
- Online: <u>www.kisqali-hcp.com</u>



Your patients are our top priority

Novartis Patient Support provides your practice with comprehensive resources to help your patients start, stay, and save on KISQALI.

We'll help you get your patients started and guide them along the way with:

- Dedicated assistance with insurance and reimbursement
- Personalized support for your patients on therapy
- Single point of contact for you and your patients

Our offerings include:



Insurance Support

We help to minimize the hassle of navigating insurance and reimbursement barriers.



Financial Support

We connect and deliver your patients to relevant savings support.

<u></u>	
 ✓ — 	
✓ —	
✓ —	
✓ —	

Clinical Testing and Support

We provide workflow support and options for testing.



Ongoing Support

We provide resources and ongoing, personalized support to help your patients along their treatment journey.



Questions?

Call Novartis Patient Support at **866-433-8000**, Monday-Friday from 8:00 AM-8:00 PM ET, excluding holidays. Visit <u>www.kisqali-hcp.com</u> for more information.

The information herein is provided for educational purposes only. Novartis cannot guarantee health plan or reimbursement. Coverage and reimbursement may vary significantly by health plan, patient, and setting of care. It is the sole responsibility of the health care provider to select the proper codes and ensure the accuracy of all statements used in seeking coverage and reimbursement for an individual patient.

Getting patients started

Novartis Patient Support will work with your practice to help your patient start on KISQALI. Begin the process by completing the Start Form. We have outlined the key information below to help ensure a smoother process for your office and your patient.

Novartis Patient Support	KISQALI* (ribocicilib) START FORM				
		Novartis Patient Support	erd Name* Date of Bats (MA DO YYY)	(+ KISQALI* (ribociciib) 51	ARTFORM
Bectrocardiogram (BCC) Testing Support Only: Deck this box and complete all hgring like fields below if you exal dile to	emplyour patient in EOG testing aupport only land to other antisional		Testing Support aport where will your patient complete their first ECOP an enrouble basis of their Trans. The	in-hone in-office ECCLine	pport ded
Please throat all fields on this form to earn's its Nonarita Patient Support. 1. Patient Information Please industry or patient type:NevD	inting	No protosono Please and t	nacy Posseindiate shere you waddike he prescription a prescriptione to he patient's payor mandated specially pr		
FastName* LastName* Set for Circle Ube* _ Main _ Fee	noie Data Mandel - Instance on participants and and and		The prescription to our office for disperse Preserved Phase Preserved The prescription to the specially phermacy lists	nacyThoreNamber PreferredPharmac editriou	yfm
Addews 76: PD Dolf * Object Dolf * Object Dolf * Date 22* Lipite permission in decides my personal hadfine nitro matcare in the following Car	OKISLeav Noomal No Preferred LanguageCryptalSpanish Other rejuer Spatianal:	7. Primary Diagnosis Code	ame Specially Pharmecy Phone Number Specially P a static Breact Cancer [HH-, HEF2 Early Breact Canc		
Canagiver Name Canagiver Phone Number - Initianayou added through non-matering out and such	Relationship to Pullent	Frimary KD-NI-CM Code /r Secondary KD-NI-CM Code /r B. Pharmacy Prescription	uppicable)		
2. Patient Authorization and Additional Enrolment Consents Inserved and agree to the Patient Authorization or page 3.		For advanced or metashific brea	cancer, the recommended starting does is 600 mg. For ear prists does for your patient in the table below by checking a 2008/92 Procession of The Marine Americania	ly bread cancer. The recommended starting angle box in sech applicable column	pdese METALS
Reparition and and a chapters to the Car-Rep Real Remained Landstaces and the spectral sectors are spectral to the spectral sectors are	Exce SMACCOTYPY) EXCELLENCE SERVER Excellence of the server of the server of the server of the server server of the server of the server of the server of the server of the server presented on the server of the server of the server of the server of the server server of the server of the serv	MBLK23 KitGAD*Rowking box200mg	KRICHLAIKOng Dear/fink 3 Habitsper Sy KRICHLAIKOng Dear/fink 2 Habitsper Sy KRICHLJ20Cong Dear/fink 1 Habitsper Sy KRICHLJ20Cong Dear/fink 1 Habitsper Sy	NSQAL/peckaging convertine28-day cyclosocia, which related a 20-day match ulf haldeds, followed by 7 days of	1000
Sitesamore Information Passer data coordinate of the patient's medical and preception a present prime reserver. Creck all that apply*PrimaryBocandaryPrimarytionPrim 4. Presenting information		Lostify the above therapy lanead preached 1950/41 to the paties and particle providers (Navaria's) rearrange in the tarm and will statis highly terratematic to approve terratematic their responsibility of the formation to the statistical three discussed the Navaria R	ally reconsery and this information is accurate to the best of ranned on the form (certify that any medication reconset the the Neuronic Point Annaburson Formation), rec, and its and othered its wate, hands, or borners entermeditor central regarders care and out for menuneration of any sort (and entity as all any time.	om/Kowstin/Flormaceuticals/Corporation / invice providers (191947), will be used only / the last neitobarsamened is any form Lacken and that Novertis and VPN ² may review, cha done under HIPAA and state taw to disclor	ts affiliates for the patient whetpe that right or ertheir
	Nucleus Nume	puttent by phone, text, and small			
	Non Curited Name Mon Curited Name	Prescriber Signature (Dep	noe as Wetten) (Substitution Permissible) Press Internet bing guidelines for electronic prescriptions (Fage		100mmp*
	RosTa*	ATTN: Please to corry our in	es priscribing-gademes for excitorix prescriptoris er ag	people.	
Tax D'Auréer Blake Lorense Funder Disk D'Auréer Blake Lorense Funder Page 1473 Completier effect from samp disk Black There may di Achievengetier Black There may di	Patertisport (00-01-35)	Popearts	SendFax BOO-BI-4508 0064-433-6 Complete enfer form and/as to Noar to Adent Suppo An Incomplete Start Frem may defay the start	1000 rtu: 800-414-3588.	50411

- > Please indicate if you would like to enroll your patient in ECG testing support only, located at the top of the first page
- ▶ Sections 1-2: are to be filled out by the patient or their authorized representative
 - Obtain patient and/or authorized representative consent by signature
 - Ensure your privately insured patient checks the appropriate box in section 2 to sign up for Novartis Patient Support Co-Pay Plus
 - Remind your patient about the appropriate box to check in section 2 if they are interested in signing up for ongoing support from their dedicated Novartis Patient Support team
- ▶ Sections 3-8: are to be filled out by the prescriber
 - · It is important to review and capture all necessary additional information prior to initiating therapy
 - · Include front and back copies of patient's medical and prescription insurance cards to allow us to verify all of their benefits
 - · Please include your preference of specialty pharmacy, if any, and be sure to fill in the pharmacy name, phone number, and fax number
 - Please don't forget to sign and date the prescriber attestation
 - Complete the ECG Testing Support section, including where your patient will have their first ECG completed (in-office or at home) and if a portable ECG device is needed by your office
 - Be sure to choose the appropriate product and dose when filling out the table in section 8
- > An incomplete Start Form may delay the start of treatment

Please see full Prescribing Information.





Novartis Pharmaceuticals Corporation East Hanover, New Jersey 07936-1080

© 2024 Novartis